Ying ZHENG, Yi YANG, Huagang PENG, et al. Therapeutic effect of polyclonal lipoprotein SA2275 antibodies on Staphylococcus aureus-induced brain abscess in mice[J]. Journal of Third Military Medical University, 2020, 42(16): 1655-1662.
DOI:
Ying ZHENG, Yi YANG, Huagang PENG, et al. Therapeutic effect of polyclonal lipoprotein SA2275 antibodies on Staphylococcus aureus-induced brain abscess in mice[J]. Journal of Third Military Medical University, 2020, 42(16): 1655-1662. DOI: 10.16016/j.1000-5404.202002210.
Therapeutic effect of polyclonal lipoprotein SA2275 antibodies on Staphylococcus aureus-induced brain abscess in mice
To investigate the ability of specific polyclonal antibodies against
Staphylococcus aureus
(
S. aureus
) lipoprotein SA2275 to penetrate the blood-brain barrier for inhibiting the formation of
S. aureus
-induced brain abscess in mice.
Methods
2
We immunized BALB/c mouse mice with purified recombinant
S. aureus
lipoprotein SA2275 expressed in
Escherichia coli
to obtain specific mouse polyclonal antibodies against SA2275 (anti-SA2275). In a C57BL/6 mouse model of brain abscess induced by injecting
S. aureus
strain Newman into the brain
we tested the titer of anti-SA2275 in the brain tissue using ELISA following intraperitoneal injection of the antibodies to evaluate the ability of the antibodies to pass through the blood-brain barrier. The bacterial load in the mouse brain was determined by gradient dilution bacterial counting
and the size of the brain abscess was evaluated on serial sections.
Results
2
The recombinant SA2275 protein with a high purity was successfully obtained. The results of ELISA showed that immunization of the mice with the recombinant SA2275 protein resulted in a high titer of anti-SA2275 reaching 1:51 200. In the mouse models of
S. aureus
-induced brain abscess
the presence of the antibodies was detected in the brain tissue after intraperitoneal injection of anti-SA2275. Treatment with anti-SA2275
as compared with blank control mouse serum
significantly reduced the size of the brain abscess and lowered the bacterial load in the brain tissues of the mice.
Conclusion
2
In mouse models of
S. aureus
-induced brain abscess
intraperitoneally injected lipoprotein SA2275-specific antibodies can penetrate the blood-brain barrier to reach the brain tissue and inhibit the formation of brain abscess and bacterial colonization
suggesting the potential of the antibodies for treatment of
S. aureus
-induced brain abscess.
关键词
Keywords
references
BROUWER M C, COUTINHO J M, VAN DE BEEK D. Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis[J]. Neurology, 2014, 82(9): 806-813. DOI: 10.1212/WNL.0000000000000172.
PATEL K, CLIFFORD D B. Bacterial brain abscess[J]. Neurohospitalist, 2014, 4(4): 196-204. DOI: 10.1177/1941874414540684.
BROUWER M C, TUNKEL A R, MCKHANN G M Ⅱ, et al . Brain abscess[J ] . N Engl J Med, 2014, 371(5): 447-456. DOI: 10.1056/nejmra1301635.
WOODHOUSE A. Bacterial meningitis and brain abscess[J]. Medicine, 2017, 45(11): 657-663. DOI: 10.1016/j.mpmed.2017.08.012.
MVHLEN S, DERSCH P. Anti-virulence strategies to target bacterial infections[J]. Curr Top Microbiol Immunol, 2016, 398: 147-183. DOI: 10.1007/82_2015_490.
BALDWIN A C, KIELIAN T. Persistent immune activation associated with a mouse model of Staphylococcus aureus-induced experimental brain abscess[J ] . J Neuroimmunol, 2004, 151(1/2): 24-32. DOI: 10.1016/j.jneuroim.2004.02.002.
ZHENG Y, SHANG W L, PENG H G, et al . Virulence determinants are required for brain abscess formation through Staphylococcus aureus infection and are potential targets of antivirulence factor therapy[J ] . Front Microbiol, 2019, 10: 682. DOI: 10.3389/fmicb.2019.00682..
SHANG W L, RAO Y F, ZHENG Y, et al . B-lactam antibiotics enhance the pathogenicity of methicillin-resistant Staphylococcus aureus via SarA-controll ed lipoprotein-like cluster expression[J ] . mBio, 2019, 10(3): e00880-e00819. DOI: 10.1128/mBio.00880-19..
BLOCH O, PAPADOPOULOS M C, MANLEY G T, et al . Aquaporin-4 gene deletion in mice increases focal edema associated with staphylococcal brain abscess[J ] . J Neurochem, 2005, 95(1): 254-262. DOI: 10.1111/j.1471-4159.2005.03362.x.
TACCONELLI E, CARRARA E, SAVOLDI A, et al . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J ] . Lancet Infect Dis, 2018, 18(3): 318-327. DOI: 10.1016/S1473-3099(17)30753-3.
GUARNER F, MALAGELADA J R. Gut flora in health and disease[J]. Lancet, 2003, 361(9356): 512-519. DOI: 10.1016/s0140-6736(03)12489-0.
SAYLOR C, DADACHOVA E, CASADEVALL A. Monoclonal antibody-based therapies for microbial diseases[J]. Vaccine, 2009, 27(Suppl 6): G38-G46. DOI: 10.1016/j.vaccine.2009.09.105.
CHOW S K, CASADEVALL A. Monoclonal antibodies and toxins: a perspective on function and isotype[J]. Toxins (Basel), 2012, 4(6): 430-454. DOI: 10.3390/toxins4060430.
PARDRIDGE W M. Biopharmaceutical drug targeting to the brain[J]. J Drug Target, 2010, 18(3): 157-167. DOI: 10.3109/10611860903548354.
AZAD T D, PAN J, CONNOLLY I D, et al . Therapeutic strategies to improve drug delivery across the blood-brain barrier[J ] . Neurosurg Focus, 2015, 38(3): E9. DOI: 10.3171/2014.12.FOCUS14758.
FLESSNER M F, DEDRICK R L. Tissue-level transport mechanisms of intraperitoneally-administered monoclonal antibodies[J]. J Control Release, 1998, 53(1/2/3): 69-75. DOI: 10.1016/s0168-3659(97)00238-1.
MCLOUGHLIN A, ROCHFORT K D, MCDONNELL C J, et al . Staphylococcus aureus -mediated blood-brain barrier injury: an in vitro human brain microvascular endothelial cell model[J ] . Cell Microbiol, 2017, 19(3). DOI: 10.1111/cmi.12664..
NGUYEN M T, GÖTZ F. Lipoproteins of gram-positive bacteria: key players in the immune response and virulence[J]. Microbiol Mol Biol Rev, 2016, 80(3): 891-903. DOI: 10.1128/MMBR.00028-16.